U.S. starts seeking drugmakers' views in turning Trump's pricing deals into law
Source: SeekingAlpha
2026-03-20 08:38:07 ET
More on Eli Lilly, Johnson & Johnson, etc.
- Roche Vs. Eli Lilly: Nvidia Deals, Obesity Battles Stoke Rivalry (I'd Buy Both)
- Novo Nordisk: The Illusion Of Cheap
- Novo Nordisk - Enough Is Enough: 5 Reasons It's Time To Sell (Rating Downgrade)
- Eli Lilly, Biogen/ Eisai win U.K. review for use of Alzheimer’s drugs in NHS
- Lilly trades flat as adverse events overshadow trial win for next-gen obesity drug
Read the full article on Seeking Alpha
For further details see:
U.S. starts seeking drugmakers’ views in turning Trump's pricing deals into law
GlaxoSmithKline PLC
NASDAQ: GSK
GSK Trading
-0.44% G/L:
$51.91 Last:
2,379,187 Volume:
$52.17 Open:
GSK Latest News
March 13, 2026 11:44:00 am
GSK's RSV Vaccine, AREXVY, Approved in US for Expanded Age Indication in Adults Aged 18-49 Years at Increased Risk
February 23, 2026 01:13:00 pm
Bora Pharmaceuticals and GSK Sign $250M Five Year Global Manufacturing Contract
GSK Stock Data
$120,291,791,432
2,019,018,428
0.4%
538
N/A
Pharmaceuticals
Healthcare
GB
London
